Management of Trigeminal Neuralgia During Pregnancy
Trigeminal neuralgia (TGN) is a debilitating painful condition which may manifest in pregnant females. It is a medical challenge for pain physicians in view of the limited therapeutic options during pregnancy and lack of adequate knowledge of this unique situation. Utility of the commonly used anti-epileptic drugs (AEDs) is questionable due the risk of teratogenic effect on fetus. Furthermore, there are not enough evidences regarding the safety of interventional procedures employed for TGN during pregnancy. When such a scenario is encountered, the management needs to be modified considering its implications on both mother and fetus.
- 2.FDA pregnancy risk information: an update. Available from: https://www.drugs.com/pregnancy-categories.html.
- 3.Australian Department of Health. Therapeutic Goods Administration. Prescribing medicines in pregnancy database. Available from: http://www.tga.gov.au/hp/medicines-pregnancy.htm. Accessed Apr 24, 2018.
- 10.Parmar BS, Shah KH, Gandhi IC. Baclofen in trigeminal neuralgia—a clinical trial. Indian J Dent Res. 1989:109–13.Google Scholar
- 13.Baclofen and pregnancy: birth defects and withdrawal symptoms. Prescrire Int. 2015; 24:214.Google Scholar
- 21.Gilbert-Barness E. Teratogenic causes of malformations. Ann Clin Lab Sci Spring. 2010;40:99–114.Google Scholar
- 25.American College of Radiology. ACR-SPR practice parameter for imaging pregnant or potentially pregnant adolescents and women with ionizing radiation. Available from: http://www.acr.org/media/ACR/Documents/PGTS/guidelines/Pregnant_Patients.pdf.